Current knowledge on the neuroprotective and neuroregenerative properties of citicoline in acute ischemic stroke

Mikhail Yu Martynov
Eugeny I Gusev
Department of Neurology, Neurosurgery and Medical Genetics, Russian National Research Medical University, Moscow, Russia

Abstract: Ischemic stroke is one of the leading causes of long-lasting disability and death. Two main strategies have been proposed for the treatment of ischemic stroke: restoration of blood flow by thrombolysis or mechanical thrombus extraction during the first few hours of ischemic stroke, which is one of the most effective treatments and leads to a better functional and clinical outcome. The other direction of treatment, which is potentially applicable to most of the patients with ischemic stroke, is neuroprotection. Initially, neuroprotection was mainly targeted at protecting gray matter, but during the past few years there has been a transition from a neuron-oriented approach toward salvaging the whole neurovascular unit using multimodal drugs. Citicoline is a multimodal drug that exhibits neuroprotective and neuroregenerative effects in a variety of experimental and clinical disorders of the central nervous system, including acute and chronic cerebral ischemia, intracerebral hemorrhage, and global cerebral hypoxia. Citicoline has a prolonged therapeutic window and is active at various temporal and biochemical stages of the ischemic cascade. In acute ischemic stroke, citicoline provides neuroprotection by attenuating glutamate excitotoxicity, oxidative stress, apoptosis, and blood–brain barrier dysfunction. In the subacute and chronic phases of ischemic stroke, citicoline exhibits neuroregenerative effects and activates neurogenesis, synaptogenesis, and angiogenesis and enhances neurotransmitter metabolism. Acute and long-term treatment with citicoline is safe and in most clinical studies is effective and improves functional outcome.

Keywords: ischemic stroke, neuroprotection, neuroregeneration, cell membranes, oxidative stress

Introduction
Stroke is one of the leading causes of mortality and long-lasting disability.1 Almost one-fourth of the patients die within the first year after insult,2 and among the survivors nearly one-third have restrictions in daily activities and require medical and social assistance.1,3

Stroke is classified into ischemic stroke, intracerebral hemorrhage, subarachnoid hemorrhage, and cerebral venous sinus thrombosis. Ischemic stroke is the most prevalent type and accounts for 75%–85% of all the strokes.

Current concepts in pathophysiology of cerebral ischemia
Originally, the concept of ischemic core and penumbra was introduced by Astrup et al.4 The last few decades have seen major advances in the understanding of the pathophysiology of cerebral ischemia. Recent data take into account that during cerebral ischemia the entire neurovascular unit is involved and that the temporal and spatial evolution of
ischemic injury is influenced by many factors, which include age, vascular risk factors, comorbidities, site and diameter of the occluded vessel, adequacy of collateral blood flow, systolic blood pressure (BP) and perfusion pressure, glucose metabolism, hematocrit, and other parameters.3–7

After the interruption of blood flow, ischemic injury develops heterogeneously; in the early minutes and hours after the onset of ischemia, the core may contain multiple sites of injury, which del Zoppo et al7 characterized as “mini-cores”, that are surrounded by “mini-penumbras”, which with time, depending on the systemic blood pressure, local perfusion, and metabolic needs, transform into homogeneous necrotic core.8 In the ischemic core, cerebral blood flow (CBF), cerebral blood volume (CBV), and local cerebral metabolic rates of oxygen (CMRO2) and glucose (CMRglc) are severely decreased.9 Experimental and clinical studies indicate that the ischemic threshold for progression to infarction is 5–8 mL 100 g−1 min−1 within the first hours after stroke onset, but rises progressively to reach −12–25 mL 100 g−1 min−1 if CBF is not restored and metabolic needs increase.10,11

The tissue surrounding the core of ischemic lesion is divided based on perfusion threshold into “penumbra” and “oligemia”. Baron et al6 defined penumbra as “a hypoperfused and functionally impaired ischemic tissue which is at risk for infarction”. In the penumbra region, blood flow is decreased to −12–25 mL 100 g−1 min−2, the oxygen extraction fraction and local CMRglc are increased, oxygen metabolism is preserved relative to CBF, and the CBV is either normal or elevated.8,11 The resulting elevated CMRglc/CBF ratio reflects various degrees of metabolism–blood flow dissociation.12 The extent and temporal evolution of penumbra varies, and according to most experimental and clinical studies brain tissue remains viable for hours after stroke.5 Electrophysiologically, the penumbra region is characterized by spontaneously occurring peri-infarct depolarizations (PID), which bear a resemblance to spreading depression of cortical electrical activity. In the penumbra region, the transient hyperperfusion in response to PID is diminished or absent and recovery from depolarization state is delayed.13 Repeated PIDs lead to depletion of ATP storage14 and have an adverse effect on microcirculation with progressive local metabolism–blood flow uncoupling15 and may lead to necrosis.16

The oligemic area represents a region with a reduced blood flow (−25–35 mL 100 g−1 min−1), normal oxygen consumption, and elevated CBV and oxygen extraction fraction. In most cases, the oligemic area is not at risk of infarction; however, prolonged systemic hypotension, increased intracranial pressure, decreased perfusion pressure, and hyperglycemia may aggravate perfusion and metabolic deficit to penumbra levels.6

**Penumbra as a therapeutic target**

Penumbra is considered as the primary target for therapy. Several approaches have been proposed for the recovery of brain cells during cerebral ischemia.17–20 Restoration of blood flow by thrombolysis or mechanical thrombus extraction during the first few hours of ischemic stroke, which is one of the most effective treatments, leads to a better functional and clinical outcome.17 Presently, 5%–20% of patients with acute ischemic stroke are treated with thrombolysis and/or thromboextraction.18

The other direction of treatment of acute cerebral ischemia, which has been explored in numerous experimental and clinical studies, is neuroprotection. Initially, neuroprotection was mainly targeted at protecting gray matter and interrupting a certain biochemical event. Although most of the neuroprotective agents proved to be effective in reducing infarct size and improving functional outcome in experimental studies, the translation to clinical trials was mainly disappointing.19 During the past few years, the transition from a purely neuron-oriented view toward a more integrative approach, which includes salvaging the whole neurovascular unit, is observed, and multimodal drugs, which are targeted at various temporal and biochemical stages of ischemic cascade, are tested in experimental and clinical trials.20

**Citicoline**

Citicoline, also called cytidine diphosphohate (CDP)-choline, is a natural compound and an intermediary in the biosynthesis of phosphatidylcholine – the structural phospholipid of cell membranes.21 Citicoline is composed of two molecules: cytidine and choline. Cytidine and choline separately pass through the blood–brain barrier (BBB), enter brain cells, and act as substrates for intracellular synthesis of CDP-choline.22,23

**Experimental and clinical data**

Citicoline has been shown to be effective in a variety of experimental and clinical disorders of the central nervous system (CNS), including acute and chronic cerebral ischemia, intracerebral hemorrhage, global cerebral hypoxia, and neurodegenerative diseases.24–28 Pharmacological actions of citicoline in the CNS are pleiotropic, affect various cell structures and biochemical pathways, and include neuroprotective and neuroregenerative effects.
In experimental models of focal or global cerebral ischemia, citicoline has been proven to have an extended therapeutic window and exhibit effects at several stages of the ischemic cascade. In citicoline alone or in combination with rt-PA or neuroprotective drugs improved neurological functions and reduced infarct size. Moreover, it has been shown that the effects of citicoline vary with dose, and that larger doses provide greater reduction of infarct volume and better improvement of neurological symptoms. In a meta-analysis, Bustamante et al summarized the results of 14 experimental studies on ischemic stroke (522 animals, 280 in the citicoline and 242 in the control group). Citicoline reduced the infarct volume compared with the control group both in permanent (25.4%, 95% confidence interval [CI]: 17.6%–33.3%) and transient (30.2%, 95% CI: 15.3%–45.1%) ischemia models and seemed to be equally effective at low (≤250 mg) and high (>250 mg) doses (27.4%, 95% CI: 14.6%–40.2% and 27.4%, 95% CI: 18.2%–36.5%, respectively). Also, the efficacy of citicoline in reducing infarct volume was better when the drug was administered in multiple doses than in a single dose (31.1%, 95% CI: 18.8%–43.5% vs. 22.6%, 95% CI: 14.1%–31.1%, P<0.0001). Combined therapy with other drugs led to a greater decrease in infarct volume: 40.2% (95% CI: 27.3%–53.1%) reduction in cotreated animals vs 24.0% (95% CI: 16.0%–31.6%) reduction in monotreated animals. Data from neurological outcome were obtained in 176 animals (104 citicoline-treated animals and 72 controls). Citicoline administration led to a better neurological recovery (20.2% compared with the control group, 95% CI: 6.8%–33.7%).

In most of the clinical studies, citicoline has shown effectiveness in reducing neurological symptoms and disability (Table 1). Davalos et al in a meta-analysis of four studies (1,372 patients, 789 in citicoline group and 583 in placebo group) demonstrated that citicoline significantly improved global recovery (BI ≥95, mRS ≤1, and NIHSS ≤1) at 3 months with the best outcome in the 2,000 mg group. Global recovery was also achieved in a subgroup of patients not treated with rt-PA (1,246 patients, odds ratio [OR]: 1.35, 95% CI: 1.10–1.65). Treatment with citicoline also increased the probability of recovering full daily living activities (BI ≥95) and functional capacity (mRS ≤1) by 29% (95% CI: 3%–62%) and 42% (95% CI: 8%–88%), respectively. Saver assessed ten placebo controlled clinical trials in patients with ischemic stroke or spontaneous intracerebral hemorrhage. Among 1,921 patients with ischemic stroke, verified by computed chromatography (CT)/magnetic resonance imaging (MRI) (five trials), 1,100 received citicoline and 821 were placed in placebo group. Patients treated with citicoline showed significant reduction in the frequency of death or dependency at follow-up: 57.4% events in citicoline group vs 65.7% in placebo group, χ²=13.22, OR: 0.70, 95% CI: 0.58–0.85, P=0.00027. Moreover, analysis confined to four largest trials with a more homogenous group of patients also yielded a significant positive effect of citicoline: χ²=17.66, OR: 0.66, 95% CI: 0.55–0.80, P=0.00027. In another analysis, 4,191 patients with acute ischemic stroke received oral citicoline (500–4,000 mg/day) for a period of at least 6 weeks, and 125 patients continued the treatment for 12 weeks. Citicoline administration led to a dose-dependent improvement in neurological deficit measured by NIHSS, BI, and mRS. In addition, better improvement was observed in patients with extended treatment.

The ICTUS trial
One of the most recent multicenter studies – the ICTUS trial – showed neutral results (Table 1). In this trial, patients were randomly assigned to citicoline or placebo group. The primary end point at 90 days was a global recovery test that combined NIHSS (≤1), mRS (≤1), and Barthel Index (≥95). The secondary outcome measures included separate analyses of NIHSS, BI, and mRS, comparison of the mRS scores between groups, and the absolute difference in the NIHSS scores between baseline and 90 days. The trial was stopped prematurely after the third interim analysis (complete analysis of 2,078 patients) for failure to produce positive results.

However, in spite of absence of positive results, several aspects of this trial deserve further attention:
1. The absolute difference in the NIHSS between baseline and 90 days (raw average improvement) in the per-protocol study was –2.18 in the citicoline group compared with –0.91 in the placebo group (effect size 1.26, 95% CI: 0.99–2.53, P=0.051).
2. Patients with less severe strokes (NIHSS =8–14) appeared to respond better to the citicoline treatment. A subgroup analysis (intention-to-treat analysis [ITT]) and per-protocol analysis [PPA]) demonstrated more favorable effects of citicoline in patients with less severe strokes (ITT, P=0.0209; PPA, P=0.0043). Generally, patients in the ICTUS trial had more severe strokes than in the previous studies: median NIHSS in the ICTUS trial was 15 compared with 14 in the meta-analysis by Davalos et al. Moreover, in the meta-analysis, median NIHSS score in patients with 2,000 mg citicoline was only 13.
3. Citicoline also led to a better outcome in patients not treated with rt-PA (ITT, P=0.0413; PPA, P=0.0956). In the ICTUS trial, almost 50% of the patients in both...
## Table 1 Major clinical trials of citicoline in ischemic stroke

<table>
<thead>
<tr>
<th>Study</th>
<th>Design</th>
<th>Size (citicoline/controls)</th>
<th>Daily dose/delivery mode/duration</th>
<th>Time to treatment in citicoline group (hours)</th>
<th>Baseline NIHSS in citicoline group</th>
<th>Primary outcome measure/time/result</th>
<th>Secondary outcome measures and post hoc analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tazaki et al37</td>
<td>Randomized, placebo-controlled, multicenter</td>
<td>272 (133/139)</td>
<td>1,000 mg/iv/2 wk</td>
<td>11.4% &lt;24 hours</td>
<td>Not performed</td>
<td>Global improvement rating/2 wk/positive Global usefulness rating/2 wk/positive</td>
<td>Not performed</td>
</tr>
<tr>
<td>Clark et al38*</td>
<td>Randomized, placebo-controlled, multicenter</td>
<td>259 (194/65)</td>
<td>a. 500 mg/orally/6 wk</td>
<td>Mean – 14.7</td>
<td>Mean – 12.8</td>
<td>BI (5 strata)/12 wk/positive in 500 mg and 2,000 mg groups Complete functional recovery (BI ≥95) and global recovery score (mRS ≤1 and NIHSS ≤1) better in 500 mg vs placebo (P &lt;0.05)</td>
<td>Complete functional recovery (BI ≥95) and global recovery score (mRS ≤1 and NIHSS ≤1) better in 500 mg vs placebo (P &lt;0.05)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>66 (1,000 mg)</td>
<td>b. 1,000 mg/orally/6 wk</td>
<td>Mean – 14.7</td>
<td>Mean – 11.6</td>
<td></td>
<td>Post hoc analysis: global recovery test (BI ≥95, mRS ≤1, NIHSS ≤1) and complete functional recovery (BI ≥95) better in citicoline patients with baseline NIHSS ≥8 (P &lt;0.05)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>66 (2,000 mg)</td>
<td>c. 2,000 mg (1,000 mg ×2)/orally/6 wk</td>
<td>Mean – 14.6</td>
<td>Mean – 13.2</td>
<td></td>
<td>Post hoc analysis: mRS ≤1, NIHSS ≤1, global recovery test (BI ≥95, mRS ≤1, NIHSS ≤1) better in citicoline (P &lt;0.05)**</td>
</tr>
<tr>
<td>Clark et al39</td>
<td>Randomized, placebo-controlled, multicenter</td>
<td>394 (267/127)</td>
<td>500 mg/orally/6 wk</td>
<td>Mean – 11.7</td>
<td>Mean – 13.3</td>
<td>BI (5 strata)/12 wk/primary planned analysis unreliable and not completed Post hoc analysis: global recovery test, mRS ≤1, NIHSS ≤1, complete functional recovery (BI ≥95) better in patients &gt;70 years, not treated with r-tPA, and with baseline NIHSS &lt;14 (P &lt;0.041)**</td>
<td>Post hoc analysis: global recovery test (BI ≥95, mRS ≤1, NIHSS ≤1) and complete functional recovery (BI ≥95) better in citicoline (P &lt;0.05)**</td>
</tr>
<tr>
<td>Clark et al40</td>
<td>Randomized, placebo-controlled, multicenter</td>
<td>899 (453/446)</td>
<td>2,000 mg (1,000 mg ×2)/orally/6 wk</td>
<td>Mean – 13.0</td>
<td>Mean – 13.9</td>
<td>NIHSS score change ≥7 points/12 wk/citicoline not effective (52% citicoline vs 51% placebo) Post hoc analysis: mRS &lt;1, NIHSS &lt;1, global recovery test (BI ≥95, mRS ≤1, NIHSS ≤1) better in citicoline (P &lt;0.05)**</td>
<td>Post hoc analysis: citicoline more effective in patients &gt;70 years, not treated with r-tPA, and with baseline NIHSS &lt;14 (P &lt;0.041)**</td>
</tr>
<tr>
<td>Davalos et al11 (ICTUS trial)</td>
<td>Randomized, placebo-controlled, multicenter</td>
<td>2,298 (1,148/1,150)</td>
<td>a. 2,000 mg (1,000 mg ×2)/iv/first 3 days</td>
<td>Median – 6.5</td>
<td>Median – 15</td>
<td>Global recovery test (BI ≥95, mRS ≤1, NIHSS ≤1)/12 wk/citicoline not effective Post hoc analysis: citicoline more effective in patients &gt;70 years, not treated with r-tPA, and with baseline NIHSS &lt;14 (P &lt;0.041)**</td>
<td>Post hoc analysis: citicoline more effective in patients &gt;70 years, not treated with r-tPA, and with baseline NIHSS &lt;14 (P &lt;0.041)**</td>
</tr>
</tbody>
</table>

Notes: *The proportion of patients with preexisting medical conditions was highest in the 1,000 mg group; **P=0.06, difference between citicoline and placebo groups in NIHSS score ≤1; ***P=0.096 in patients not treated with r-tPA in per-protocol study.

Abbreviations: NIHSS, National Institute of Health Stroke Scale; iv, intravenous; wk, weeks; BI, Barthel Index; mRS, modified Rankin Scale; r-tPA, recombinant-tissue plasminogen activator.
groups received thrombolysis compared with 12.6% in the group with 2,000 mg citicoline in the meta-analysis and 5%–20% in a standard stroke practice. High percentage of thrombolyses in the ICTUS trial may have biased the results, leading to a maximal functional recovery due to rt-tPA and attenuating effects by citicoline.

4. The investigators also reported that the effect of citicoline seemed to be more beneficial in patients older than 70 years compared with those aged ≤70 years (ITT, P=0.0014; PPA, P<0.0001). This finding may deserve a further analysis, since age-dependent modification in metabolism was observed for drugs acting on central nervous and cardiovascular systems.

Main mechanisms of action
Neuroprotective action
The effectiveness of citicoline in acute ischemic stroke may be due to its pleiotropic neuroprotective functions (Table 2) with stabilization of cell membranes, attenuation of glutamate exitotoxicity, oxidative stress, apoptosis, and endothelial barrier dysfunction.

Glutamate exitotoxicity
Within a few minutes after the onset of cerebral ischemia in the core of ischemic injury, ATP-dependent ion pumps fail and intracellular Na+ increases, resulting in the release of glutamate into the extracellular space. Citicoline protects the membranes by inhibiting glutamate release. Hurtado et al in a rat model of combined CCA and MCA occlusion demonstrated that citicoline inhibited ischemia-induced increase in glutamate concentrations. In addition, incubation of cortical neurons with citicoline prevented glutamate release induced by oxygen and glucose deprivation (OGD). Pretreatment of cerebellar granule neurons with CDP-choline prior to glutamate administration led to a dose- and time-dependent reduction of glutamate-induced excitotoxicity.

Glutamate clearance is regulated by excitatory amino acid transporters (EAATs), and citicoline may modulate glutamate actions through induction of EAATs. At present, five EAATs have been cloned and characterized. Most of them are tissue-specific, and downregulation of glutamate transporters may lead to neuronal death during ischemia. EAAT2 is a glutamate transporter responsible for up to 90% of all the glutamate transport. Positive clinical effect of focal overexpression of EAAT2 in reducing ischemia-induced glutamate overflow and decreasing apoptotic cell death was observed in a study by Harvey et al. Hurtado et al in a model of OGD test reported an increased EAAT2 expression and glutamate uptake in rat astrocytes. Administration of CDP-choline in a model of MCA occlusion induced EAAT2 translocation to the membrane, increased EAAT2 association to lipid rafts, and thus intensified glutamate uptake compared with saline-treated animals.

Oxidative damage
After cerebral ischemia, increased levels of reactive oxygen species are generated, which cause injury through destruction of nucleic acids, proteins, and lipids, and/or by disrupting

<table>
<thead>
<tr>
<th>Ischemic cascade level</th>
<th>Citicoline putative mode of action</th>
<th>Main effects</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cell energy balance</td>
<td>Stimulation/restoration of Na+/K+ ATPase activity</td>
<td>Cell energy deficiency correction</td>
<td>Plataris et al</td>
</tr>
<tr>
<td></td>
<td>Restoration/prevention of loss of neuronal ATP levels</td>
<td>Preservation/restoration of neuronal ionic balance</td>
<td>Hurtado et al</td>
</tr>
<tr>
<td>Glutamate exitotoxicity</td>
<td>Delay/prevention in the reversal of neuronal glutamate transporters</td>
<td>Decreased/delayed neuronal glutamate efflux</td>
<td>Hurtado et al</td>
</tr>
<tr>
<td></td>
<td>Increase in the surface fraction of EAAT2 transporter</td>
<td>Increased glutamate uptake by astrocytes</td>
<td>Hurtado et al</td>
</tr>
<tr>
<td>Oxidative cascade</td>
<td>Prevention of PL2 activation</td>
<td>Decreased FFA release</td>
<td>Adibhatla and Hatcher</td>
</tr>
<tr>
<td></td>
<td>Induction of glutathione reductase activity</td>
<td>Glutathione synthesis stimulation</td>
<td>Adibhatla et al</td>
</tr>
<tr>
<td>Apoptosis</td>
<td>Increase in the Bcl-2 expression</td>
<td>Attenuation/neuralization of Bad/Bax family proteins</td>
<td>Sobrado et al</td>
</tr>
<tr>
<td></td>
<td>Upregulation of SIRT1 protein</td>
<td>Attenuation/prevention of caspase-3 activation</td>
<td>Hurtado et al</td>
</tr>
<tr>
<td></td>
<td>Downregulation of procaspase and caspase expression</td>
<td>Attenuation/prevention of PARP cleavage and DNA damage</td>
<td>Krupinski et al</td>
</tr>
<tr>
<td>Endothelial barrier disruption</td>
<td>TJ protein regulation</td>
<td>Reduction of brain edema</td>
<td>Schabitz et al</td>
</tr>
<tr>
<td></td>
<td>Decrease in permeability of endothelial barrier and restoration of TJ proteins linear structure</td>
<td>Decrease in permeability of endothelial barrier and restoration of TJ proteins linear structure</td>
<td>Ma et al</td>
</tr>
</tbody>
</table>

Abbreviations: EAAT2, excitatory amino acid transporter 2; PL2, phospholipase 2; FFA, free fatty acids; PARP, poly (ADP-ribose) polymerase; TJ, tight junctions.
gene expression and cellular signaling.\textsuperscript{55} Phospholipase A2 (PLA2) and arachidonic acid (AA) play a key role in post-ischemic oxidative stress.\textsuperscript{36} During acute ischemia, cytosolic Ca\textsuperscript{2+}-dependent PLA2 is activated by release of glutamate and elevation of intracellular Ca\textsuperscript{2+},\textsuperscript{57} resulting in hydrolysis of phospholipids and release of free fatty acids (FFA).\textsuperscript{58} Free AA accumulates inside the cells, promotes the formation of reactive oxygen species, and amplifies the oxidative damage.\textsuperscript{55}

Citicoline may provide neuroprotection by preventing the activation of PLA2 and AA release and by modulating glutathione synthesis through choline. In a model of transient forebrain ischemia in gerbils, citicoline stabilized cell membranes, attenuated activation of PLA2 in membrane and mitochondrial fractions, and decreased AA and release of other FFA after reperfusion.\textsuperscript{46} Trovarelli et al\textsuperscript{49} demonstrated that intraventricular preconditioning with CDP-choline in a model of brain ischemia in gerbils resulted in a partial restoration of brain phosphatidylycerolcholine concentration and attenuated the release of AA including AA. Rao et al\textsuperscript{60} in a model of transient forebrain ischemia observed that CDP-choline given immediately after the onset of ischemia and at 3 hours reperfusion significantly restored the phosphatidylycerolcholine, sphingomyelin, and cardiolipin levels. Oral administration of CDP-choline in a model of brain cryogenic injury inhibited activation of PLA2 and prevented destruction of membrane phospholipids.\textsuperscript{61} Cytidine and choline, the breakdown products of citicoline, may enhance the incorporation of FFA – including AA – into phosphatidylycerolcholine and other major phospholipids. Addition of equimolar concentrations of cytidine and choline to [3H]-arachidonic acid dose-dependently increased the accumulations of [3H]-phosphatidylycerolcholine, [3H]-phosphatidylinositol, and [3H]-phospatidylethanolamine,\textsuperscript{57} thus removing the free AA, which is as a potential source of oxidative damage. In another study, citicoline administration stimulated reincorporation of AA in phosphatidylycerolcholine and thus reduced oxidative damage.\textsuperscript{60}

Citicoline through choline–S-adenosyl-L-methionine pathway may modulate synthesis of glutathione.\textsuperscript{62} Adibhatla et al\textsuperscript{49} reported that serial intraperitoneal citicoline administrations in doses 500 mg/kg in a gebril model of transient forebrain ischemia significantly increased total glutathione and glutathione reductase activity compared with the ischemia/saline group. Citicoline treatment also decreased the glutathione oxidation ratio at 6 hours, 1 and 3 days after stroke.

**Apopotosis**

Apopotosis is an orderly and energy-dependent process of programmed cell death.\textsuperscript{63} In experimental and clinical ischemic stroke, apoptotic changes are mainly confined to penumbra.\textsuperscript{64,65} Cerebral ischemia triggers both apoptotic pathways: the intrinsic or mitochondrial pathway, initiated by internal events, and extrinsic pathway, initiated by external events.\textsuperscript{66}

Several reports indicate that citicoline may attenuate/prevent apopotosis by influencing both pathways, while CDP-choline deficiency may induce apopotosic process.\textsuperscript{50,67,68} A recent study also suggests also suggest that during apopotosis, cytidine and choline incorporation into cells and intercellular CDP-choline resynthesis may be blocked.\textsuperscript{68}
et al. demonstrated that 6-hour preconditioning of cerebellar granule neurons with 100 microM CDP-choline solution significantly decreased the number of apoptotic neurons caused by glutamate excitotoxicity. Krupinski et al. in a rat model of permanent MCA occlusion showed a significant reduction in immunoreactive cells for procaspases-1, -2, -3, -6, and -8 in the ischemic area of citicoline-treated animals compared with sham-operated animals. Also, the number of cells expressing nuclear DNA fragmentation, cleaved caspase-3, and caspase-cleaved products of poly (ADP-ribose) polymerase were significantly reduced in the penumbra area of animals treated with citicoline. Preincubation of human brain microvascular endothelial cells (hCMEC/D3) with citicoline significantly decreased the number of apoptotic cells after ischemia. Sahin et al. analyzed the protective effects of citicoline alone or in combination with hypothermia. After 2 hours of MCA occlusion, both groups showed reduced number of apoptotic cells compared with saline-treated animals. In another study, in a model of bilateral CCA ligation and MCA occlusion, intraperitoneal administration of citicoline for 7 days significantly decreased apoptosis measured by TUNEL positive cells and increased the Bcl-2 expression within the border zone of necrotic core. In rats subjected to serial transient focal cerebral ischemia, repeated administration of CDP-choline significantly reduced caspase-3-positive neurons. Citicoline may also influence the apoptotic pathways in cerebral ischemia through the preservation of glutathione synthesis and prevention of ceramide generation.

LRP is a multifunctional protein expressed in neurons and astrocytes, and recent data suggest its scavenging role during phagocytosis of myelin debris, as well as during apoptotic and necrotic cell death. Prolonged citicoline administration in a model of permanent MCA occlusion significantly downregulated LRP expression in the peri-infarct (PI) region compared with saline-treated animals, suggesting decreased apoptosis, necrosis, and myelin degradation.

Of interest is also a recent finding that citicoline may upregulate Sirtuin 1 (SIRT1) expression in cultured neurons. Mammalian species have seven proteins of the Sirtuin family (SIRT1–7). SIRT1 is a protein with the highest sequence homology to Sirt2 (silent information regulator 2), and plays an important role in mediating cell cycle and apoptosis, as well as in anti-inflammatory and antioxidant responses. SIRT1 induction may attenuate expression of p53 and caspase-3. Citicoline administration (0.2 or 2.0 g/kg) in a model of permanent MCA occlusion significantly increased SIRT1 levels and led to a reduction in infarct volume in Fisher rats, but failed to upregulate SIRT1 expression and decrease infarct volume in SIRT1-deficient mice.

**Blood–brain barrier**

The BBB is characterized by the presence of tight cell–cell junctions and a lack of fenestrations at the level of cerebral microvascular endothelium. Tight cell–cell junctions are constituted by proteins belonging to occludin, claudin, and membrane-associated guanylate kinase-like proteins (zonula occludens [ZO]-1, -2, -3) family, as well as by other accessory proteins and adhesion molecules. The permeability of the BBB depends on the integrity of the tight junction (TJ) proteins. Occludin is expressed in the cerebral endothelial cells and its cytoplasmic C-terminal domain is involved in the association with cytoskeleton via ZO-1 and -2 proteins. Claudin-5 and ZO-1 are also important components for the integrity of cell barrier. Claudin-5 can reduce the permeability assessed by dextran. ZO-1 links transmembrane and skeleton proteins, and this interaction is important to the stability and function of the TJs. ZO-1 may also act as a signaling molecule that translates the state of the TJ to the interior of the cell and vice versa.

Ischemic stroke leads to a BBB disruption and increased permeability. Experimental and, to a lesser degree, clinical studies suggest that in ischemic stroke BBB disruption is a dynamic process, and the initial breakdown in most cases is followed by a partial BBB recovery, before the second increase in BBB permeability occurs. Dysregulation of the TJ proteins plays an important role in BBB permeability in stroke pathogenesis. In experimental stroke caused by MCA occlusion, a decrease in expression of claudin-5, occludin, and ZO-1, which paralleled increased BBB permeability, was observed. Schreibelt et al. demonstrated that activation of oxidative metabolism alters BBB integrity due to cytoskeleton rearrangements, and redistribution and disappearance of claudin-5 and occludin.

Several previous studies indicated that citicoline administration may attenuate brain edema, possibly through BBB stabilization. Schabitz et al. evaluated the effect of prolonged treatment with citicoline in a rat model of temporary MCA ischemia. Intraperitoneal administration of citicoline significantly reduced perifocal edema. Rao et al. reported the reduction of brain edema induced by transient forebrain ischemia in gerbils treated with citicoline. Citicoline was also dose-dependently effective in reducing brain edema and BBB permeability in the animal model of traumatic brain injury. Recently, it has been shown that LRP-1 may modulate BBB permeability, and the association of tPA with
LRP-1 leads to increase in vascular permeability and BBB opening. Citicoline administration, started 30 minutes after MCA occlusion in rats, resulted in decreased brain edema, downregulation of LRP-1, and restoration of endothelial barrier function.

In a recent study, Ma et al19 in an OGD and hypoxia endothelial barrier breakdown model (human umbilical vein endothelial cells [HUVEC] and brain microvascular endothelial cells [bEnd.3s]) examined the effect of citicoline on endothelial permeability and expressions of ZO-1, claudin-5, and occludin. Both OGD and hypoxia increased the permeability of the BBB, while citicoline dose-dependently decreased FITC-dextran endothelial permeability at low (0.1 mmol/L) and high (1.0 mmol/L) doses. Hypoxia induced significant decrease in mRNA and protein levels, as well as disappearance of normal linear structure of ZO-1, occludin, and claudin-5 in HUVECs and bEnd.3s cells. After citicoline treatment, the expression of all the above-mentioned TJ proteins was upregulated, and linear distribution of proteins was restored.

Neuroregenerative action

In the subacute and chronic phases of stroke, citicoline may exhibit neuroregenerative effects (Table 3), by activating neurogenesis, synaptogenesis, and angiogenesis, and modulate neurotransmitter metabolism and brain bioenergetics. Citicoline may facilitate recovery by enhancing synaptic growth and synaptogenesis. Citicoline administration led to the upregulation of synaptophysin in the penumbra region, which could be indicative of increased synaptic activity, since synaptophysin regulates the recovery of recycling vesicle pool and facilitates synaptic vesicle endocytosis. Administration of CDP-choline for 28 days, initiated 24 hours after MCA occlusion, enhanced dendritic complexity and spine density in pyramidal cells (layer V) in the undamaged areas of the motor cortex compared with the saline group. Analysis of dendritic integrity in the immediate border zone in the PI region revealed a difference between citicoline-treated animals and controls with the tendency to significant values (P=0.082). Treatment of primary neuronal cultures from somatosensory cortex with CDP-choline increased the neurite length, branch points, and total area occupied by neurons. Also, daily administration of CDP-choline from conception (maternal ingestion) to postnatal day 60 to Long–Evans rats resulted in a significant increase in length and branch points of apical and basal dendrites in the pyramidal neurons of somatosensory cortex layers 2, 3, and 5.

Angiogenesis is a key feature of the post-stroke neurovascular remodeling, and newly formed vessels may provide a scaffold for the migration of neural cells toward PI area. Krupinski et al70 demonstrated that citicoline induced angiogenesis by improving survival of vascular/human brain microvessel endothelial cells (hCMEC/D3) through pathways involving phosphor-extracellular signal-regulated kinase (ERK1/2) and insulin receptor substrate-1 (IRS-1). In hCMEC/D3 citicoline stimulated the expression of ERK1/2. Also, the expression of IRS-1 was increased in citicoline-treated hCMEC/D3 cells. Treatment with citicoline increased the number of CD31-positive microvessels and significantly increased the number of CD105-positive (active) microvessels in the PI area by 21st day post-stroke.

Vascular endothelial growth factor (VEGF) is an angiogenic factor that plays a key role in vascular homeostasis. In rats with permanent MCA occlusion and treated with citicoline, increased expression of VEGF compared with saline-treated animals was observed. The upregulation of VEGF may be linked to activation of IRS-1, which contributes significantly to VEGF expression.

Endothelial progenitor cells (EPC) augment collateralization, increase capillary density, and enhance neuromodulation and neurogenesis after experimental cerebral ischemia, and a higher increment in EPC during the first week in patients with lacunar stroke is associated with a better functional outcome.
Administration of 2,000 mg of citicoline from the first day of ischemic lacunar stroke led to a significant increase in circulating EPC by day 7 compared with nontreated patients\textsuperscript{106} and better clinical outcome.

**Modulation of neurotransmitter release**

Post-stroke recovery is modulated by neurotransmitters. Dopamine (DA) and acetylcholine (ACh) influence emotional, cognitive, and motor responses. Citicoline promotes changes in brain DA receptors and modulates the release of DA.\textsuperscript{107} Ischemic stroke mainly occurs in the elderly population, and aging is associated with a decrease in the number of DA and ACh receptors.\textsuperscript{93} Administration of citicoline for 7 months in doses of 100 mg/kg or 500 mg/kg per day to aging mice led to a partial recovery of receptor function and density. Treated animals displayed a dose-dependent increase in DA and ACh receptor densities, while control animals showed a significant reduction in DA and ACh receptor densities.\textsuperscript{93} Radad et al\textsuperscript{108} demonstrated that CDP-choline may reduce dopaminergic cell loss induced by MMP (+) and glutamate in primary mesencephalic cell culture. In another study, addition of various concentrations of citicoline breakdown product, choline, to the rat striatum and cerebellum slices differentially stimulated basal and evoked ACh release, indicating that free choline may be used as a source of ACh synthesis.\textsuperscript{109} Kakihana et al\textsuperscript{29} in a model of transient bilateral occlusion of common carotid arteries (after permanent occlusion of both vertebral arteries) observed that CDP-choline administration in doses of 250 mg/kg accelerated glucose utilization and restored the synthesis of acetylcholine. N-acetyl-aspartate (NAA) is a major metabolite located primarily in pyramidal neurons and axons. NAA is involved in neuronal plasticity, axon–glia signaling, mitochondrial energy, and myelin lipid metabolism and is viewed as a surrogate marker of integrity and viability of neural tissue.\textsuperscript{109} Yoon et al\textsuperscript{111} in a $^{1}$H MR spectroscopy study observed that citicoline administered for 4 weeks at a dose of 2,000 mg/day steadily increased prefrontal NAA and Cho levels after second and fourth weeks of treatment.

Citicoline may also enhance frontal lobe bioenergetics and in this way activate attention, memory tasks, and speed information processing. Silvery et al\textsuperscript{44} in a MR spectroscopy study ($^{31}$P) established that oral administration of 500 or 2,000 mg of citicoline for 6 weeks to 16 healthy men and women led to a region-specific increase in the amount of $\beta$-NTP (primarily reflects concentrations of ATP) and PCr (reflects the high-energy phosphate buffer stores), and in membrane phospholipids in frontal lobes (anterior cingulated cortex).

**Conclusion**

Experimental and clinical data support the evidence that citicoline is a multimodal drug with prolonged therapeutic window and neuroprotective and neuroregenerative effects. Citicoline acts at various temporal and biochemical stages of the ischemic cascade and attenuates glutamate excitotoxicity, oxidative stress, apoptosis, and BBB dysfunction. Citicoline also modulates neurotransmitter metabolism; enhances neuroplasticity; and activates neurogenesis, synaptogenesis, and angiogenesis. Acute and long-term treatment with citicoline is safe and in most clinical studies is effective and improves functional outcome. However, further experimental research with lower citicoline doses and stroke models corresponding to clinical practice, as well as adequately planned clinical trials, are needed.

**Disclosure**

No sources of funding were used in the preparation of this review. The authors report no conflicts of interest in this work.

**References**


